FOURTH AMENDMENT TO PATENT LICENSE AGREEMENTPatent License Agreement • March 20th, 2007 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances)
Effective the date of signature of the last party to sign this fourth amendment to license L-354-98/0 (“Fourth Amendment”), the Public Health Service (“PHS”), through the Office of Technology Transfer of the National Institutes of Health, having its principal office at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852, U.S.A., and Zonagen, Inc. (“Licensee”), a Delaware corporation, having its principal office at 2408 Timberloch Place, Suite B-4, The Woodlands, Texas 77280, agree as follows:
CONFIDENTIAL TREATMENT REQUESTED PUBLIC HEALTH SERVICE FIFTH AMENDMENT TO L-354-1998/0Fifth Amendment • March 20th, 2007 • Repros Therapeutics Inc. • Biological products, (no disgnostic substances)
This is the fifth amendment (“Fifth Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as (“PHS”), agencies of the United States Public Health Service within the Department of Health and Human Services (“HHS”), and Repros Therapeutics Inc., formerly known as Zonagen having an effective date of April 16, 1999 and having NIH Reference Number L-354-1998/0 (“Agreement”). This Fifth Amendment, having NIH Reference Number L-354-1998/5, is made between the PHS through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Repros Therapeutics Inc.,having an office at 2408 Timbeloch Place, Suite B-7, The Woodlands, TX 77280 (“Licensee”). This Fifth Amendment includes, in addition to the amendments made below, 1) a Signature Page and 2) Attachment 1 (Royalty Payment Information).
